{"title":"脂肪连接蛋白与 II 型糖尿病患者甲状腺功能障碍的关系","authors":"Sabah Qusay Abd-Alhussain, Omar Sabbar Sallman","doi":"10.30574/gscbps.2024.26.2.0066","DOIUrl":null,"url":null,"abstract":"The two most prevalent endocrine-related conditions seen in clinical practice are thyroid diseases (TD) and diabetes mellitus (DM). Diabetes mellitus and thyroid dysfunction are strongly related conditions. Numerous research investigations have reported that individuals with diabetes mellitus are more likely to have thyroid issues, and vice versa. Compared to individuals without diabetes, Type 2 Diabetes Mellitus (T2DM) patients have higher rates of both hypothyroidism and hyperthyroidism. Thyroid hormones are circulating hormones that impact various organs and tissues, have a vital role in the metabolism of proteins, fats, and carbohydrates, and can exacerbate glycemic control in individuals with Type II Diabetes Mellitus (T2DM). At the Specialized Center for Endocrinology and Diabetes – Al-Kindi Teaching Hospital in Baghdad, a case-control research was carried out. The samples were gathered between January 1, 2021, and April 1, 2021. The current study had one hundred twenty (120) volunteers, all of whom fasted for eight to twelve hours before to the test: · Thirty (30) patients suffered from diabetic mellitus type II seventeen (17) females and thirteen (13) males. · Thirty (30) were control with, sixteen (16) females and fourteen (14) males. · Thirty (30) patients had thyroid dysfunction eighteen (18) females and twelve (12) males. · Thirty (30) patients had thyroid dysfunction and diabetes mellitus type II, sixteen (16) females and fourteen (14) males. Variables such as gender, age, Body Mass Index (BMI), thyroid hormones ,Fasting Blood Sugar (FBS), Glycated Hemoglobin (HbA1c), lipid profile (TG, CHOL, LDL-C, HDL-C, VLDL-C), Adiponectin (ADP)were measured and documented from participants included in this study. According to the results of hormones, there were substantial variations in all of the hormone levels. Thyroid Stimulating Hermon (TSH) was the highest level in Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism patients(0.46 ± 6.26) µIU/mL. T3 hormone was (187.84 ± 6.12) ng/dL, the highest resultin Thyroid Dysfunction with Diabetes Mellitus type Ⅱ: Hyperthyroidism patients. T4 was highest hormonal level in Thyroid Dysfunction with Diabetes Mellitus type II: Hyperthyroidism patients which was (14.02 ± 0.56) ng/dL. Fasting blood sugar (serum) measured a highly significant differences and highest level in patients who suffered from thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (190.50 ± 12.72) mg/dL. Glycated hemoglobin (HbA1c) measured high significant differences with (11.13 ± 0.55) mmoL/L in patients of diabetes type II. Cholesterol, Triglyceride, LDL-C and VLDL-C high significant differences and highest levels were among patients with Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (209.45 ±12.29, 268.18 ±31.57, 114.24 ±13.74 and 55.98 ±5.63) mg/dL respectively, while HDL-C was significantly higher in control group. The Adiponectin had high significant differences among Thyroid Dysfunction: Hyperthyroidism patients with (17.98 ±1.43) ng/mL. In conclusion this data backs up the theory that inducing or suppressing adiponectin in individuals with thyroid dysfunction can help them in losing weight. Hypothyroid individuals with DM Type II and lipid abnormalities in their blood. This data is attributed to the idea that inducing or suppressing adiponectin in individuals with thyroid dysfunction might be a promising new treatment strategy. Adiponectin has been shown that’s involved in numerous physiological and pathological processes, including as inflammation and tissue remodeling. They may be crucial in the formation of adipose tissue and insulin resistance, and they have been linked to a number of inflammatory illnesses.","PeriodicalId":12808,"journal":{"name":"GSC Biological and Pharmaceutical Sciences","volume":"31 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of adiponectin with thyroid dysfunction in diabetes mellitus type II\",\"authors\":\"Sabah Qusay Abd-Alhussain, Omar Sabbar Sallman\",\"doi\":\"10.30574/gscbps.2024.26.2.0066\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The two most prevalent endocrine-related conditions seen in clinical practice are thyroid diseases (TD) and diabetes mellitus (DM). Diabetes mellitus and thyroid dysfunction are strongly related conditions. Numerous research investigations have reported that individuals with diabetes mellitus are more likely to have thyroid issues, and vice versa. Compared to individuals without diabetes, Type 2 Diabetes Mellitus (T2DM) patients have higher rates of both hypothyroidism and hyperthyroidism. Thyroid hormones are circulating hormones that impact various organs and tissues, have a vital role in the metabolism of proteins, fats, and carbohydrates, and can exacerbate glycemic control in individuals with Type II Diabetes Mellitus (T2DM). At the Specialized Center for Endocrinology and Diabetes – Al-Kindi Teaching Hospital in Baghdad, a case-control research was carried out. The samples were gathered between January 1, 2021, and April 1, 2021. The current study had one hundred twenty (120) volunteers, all of whom fasted for eight to twelve hours before to the test: · Thirty (30) patients suffered from diabetic mellitus type II seventeen (17) females and thirteen (13) males. · Thirty (30) were control with, sixteen (16) females and fourteen (14) males. · Thirty (30) patients had thyroid dysfunction eighteen (18) females and twelve (12) males. · Thirty (30) patients had thyroid dysfunction and diabetes mellitus type II, sixteen (16) females and fourteen (14) males. Variables such as gender, age, Body Mass Index (BMI), thyroid hormones ,Fasting Blood Sugar (FBS), Glycated Hemoglobin (HbA1c), lipid profile (TG, CHOL, LDL-C, HDL-C, VLDL-C), Adiponectin (ADP)were measured and documented from participants included in this study. According to the results of hormones, there were substantial variations in all of the hormone levels. Thyroid Stimulating Hermon (TSH) was the highest level in Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism patients(0.46 ± 6.26) µIU/mL. T3 hormone was (187.84 ± 6.12) ng/dL, the highest resultin Thyroid Dysfunction with Diabetes Mellitus type Ⅱ: Hyperthyroidism patients. T4 was highest hormonal level in Thyroid Dysfunction with Diabetes Mellitus type II: Hyperthyroidism patients which was (14.02 ± 0.56) ng/dL. Fasting blood sugar (serum) measured a highly significant differences and highest level in patients who suffered from thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (190.50 ± 12.72) mg/dL. Glycated hemoglobin (HbA1c) measured high significant differences with (11.13 ± 0.55) mmoL/L in patients of diabetes type II. Cholesterol, Triglyceride, LDL-C and VLDL-C high significant differences and highest levels were among patients with Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (209.45 ±12.29, 268.18 ±31.57, 114.24 ±13.74 and 55.98 ±5.63) mg/dL respectively, while HDL-C was significantly higher in control group. The Adiponectin had high significant differences among Thyroid Dysfunction: Hyperthyroidism patients with (17.98 ±1.43) ng/mL. In conclusion this data backs up the theory that inducing or suppressing adiponectin in individuals with thyroid dysfunction can help them in losing weight. Hypothyroid individuals with DM Type II and lipid abnormalities in their blood. This data is attributed to the idea that inducing or suppressing adiponectin in individuals with thyroid dysfunction might be a promising new treatment strategy. Adiponectin has been shown that’s involved in numerous physiological and pathological processes, including as inflammation and tissue remodeling. They may be crucial in the formation of adipose tissue and insulin resistance, and they have been linked to a number of inflammatory illnesses.\",\"PeriodicalId\":12808,\"journal\":{\"name\":\"GSC Biological and Pharmaceutical Sciences\",\"volume\":\"31 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GSC Biological and Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30574/gscbps.2024.26.2.0066\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GSC Biological and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30574/gscbps.2024.26.2.0066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
临床上最常见的两种内分泌相关疾病是甲状腺疾病(TD)和糖尿病(DM)。糖尿病和甲状腺功能障碍是密切相关的疾病。大量研究报告表明,糖尿病患者更容易出现甲状腺问题,反之亦然。与非糖尿病患者相比,2型糖尿病(T2DM)患者的甲状腺功能减退症和甲状腺功能亢进症发病率都较高。甲状腺激素是一种影响各种器官和组织的循环激素,在蛋白质、脂肪和碳水化合物的新陈代谢中起着至关重要的作用,并且会加剧二型糖尿病(T2DM)患者的血糖控制。巴格达 Al-Kindi 教学医院内分泌学和糖尿病专科中心开展了一项病例对照研究。样本收集时间为 2021 年 1 月 1 日至 2021 年 4 月 1 日。本次研究有 120 名志愿者参加,他们在测试前都禁食了 8 到 12 个小时:- 三十(30)名 II 型糖尿病患者中有十七(17)名女性和十三(13)名男性。- 三十(30)名患者为对照组,其中女性十六(16)名,男性十四(14)名。- 三十(30)名患者患有甲状腺功能障碍,其中女性十八(18)名,男性十二(12)名。- 三十(30)名患者患有甲状腺功能障碍和 II 型糖尿病,其中女性十六(16)名,男性十四(14)名。本研究对参与者的性别、年龄、体重指数(BMI)、甲状腺激素、空腹血糖(FBS)、糖化血红蛋白(HbA1c)、血脂(TG、CHOL、LDL-C、HDL-C、VLDL-C)、脂肪连蛋白(ADP)等变量进行了测量和记录。根据激素检测结果,所有激素水平都有很大差异。甲状腺功能紊乱伴 II 型糖尿病:甲状腺功能减退症患者的促甲状腺激素(TSH)水平最高(0.46 ± 6.26)µIU/mL。T3激素为(187.84 ± 6.12)纳克/分升,在甲状腺功能紊乱伴糖尿病Ⅱ型:甲减患者中结果最高:甲状腺功能亢进症患者。甲状腺功能紊乱伴糖尿病Ⅱ型:甲状腺功能亢进症患者的 T4 激素水平最高,为 (14.02 ± 0.56) ng/dL。空腹血糖(血清)测量结果差异很大,甲状腺功能紊乱伴 II 型糖尿病:甲状腺功能减退症患者的空腹血糖水平最高,为(190.50 ± 12.72)毫克/分升。在 II 型糖尿病患者中,糖化血红蛋白(HbA1c)的测量结果差异很大,为(11.13 ± 0.55)毫摩尔/升。甲状腺功能障碍伴 II 型糖尿病:甲状腺功能减退症患者的胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)和超低密度脂蛋白胆固醇(VLDL-C)差异显著且水平最高,分别为(209.45 ±12.29、268.18 ±31.57、114.24 ±13.74和55.98 ±5.63)毫克/分升,而对照组的高密度脂蛋白胆固醇(HDL-C)显著较高。甲状腺功能障碍患者的脂肪连接蛋白差异很大:甲状腺功能亢进:甲状腺功能亢进症患者的 Adiponectin 值为 (17.98 ±1.43) ng/mL。总之,这些数据支持了这样一种理论,即诱导或抑制甲状腺功能障碍患者体内的脂肪连素可以帮助他们减轻体重。甲状腺功能减退症患者伴有糖尿病II型和血脂异常。这一数据表明,诱导或抑制甲状腺功能障碍患者体内的脂肪连蛋白可能是一种很有前景的新治疗策略。研究表明,脂肪连通素参与了许多生理和病理过程,包括炎症和组织重塑。它们可能在脂肪组织的形成和胰岛素抵抗中起着关键作用,而且与许多炎症性疾病有关。
Association of adiponectin with thyroid dysfunction in diabetes mellitus type II
The two most prevalent endocrine-related conditions seen in clinical practice are thyroid diseases (TD) and diabetes mellitus (DM). Diabetes mellitus and thyroid dysfunction are strongly related conditions. Numerous research investigations have reported that individuals with diabetes mellitus are more likely to have thyroid issues, and vice versa. Compared to individuals without diabetes, Type 2 Diabetes Mellitus (T2DM) patients have higher rates of both hypothyroidism and hyperthyroidism. Thyroid hormones are circulating hormones that impact various organs and tissues, have a vital role in the metabolism of proteins, fats, and carbohydrates, and can exacerbate glycemic control in individuals with Type II Diabetes Mellitus (T2DM). At the Specialized Center for Endocrinology and Diabetes – Al-Kindi Teaching Hospital in Baghdad, a case-control research was carried out. The samples were gathered between January 1, 2021, and April 1, 2021. The current study had one hundred twenty (120) volunteers, all of whom fasted for eight to twelve hours before to the test: · Thirty (30) patients suffered from diabetic mellitus type II seventeen (17) females and thirteen (13) males. · Thirty (30) were control with, sixteen (16) females and fourteen (14) males. · Thirty (30) patients had thyroid dysfunction eighteen (18) females and twelve (12) males. · Thirty (30) patients had thyroid dysfunction and diabetes mellitus type II, sixteen (16) females and fourteen (14) males. Variables such as gender, age, Body Mass Index (BMI), thyroid hormones ,Fasting Blood Sugar (FBS), Glycated Hemoglobin (HbA1c), lipid profile (TG, CHOL, LDL-C, HDL-C, VLDL-C), Adiponectin (ADP)were measured and documented from participants included in this study. According to the results of hormones, there were substantial variations in all of the hormone levels. Thyroid Stimulating Hermon (TSH) was the highest level in Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism patients(0.46 ± 6.26) µIU/mL. T3 hormone was (187.84 ± 6.12) ng/dL, the highest resultin Thyroid Dysfunction with Diabetes Mellitus type Ⅱ: Hyperthyroidism patients. T4 was highest hormonal level in Thyroid Dysfunction with Diabetes Mellitus type II: Hyperthyroidism patients which was (14.02 ± 0.56) ng/dL. Fasting blood sugar (serum) measured a highly significant differences and highest level in patients who suffered from thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (190.50 ± 12.72) mg/dL. Glycated hemoglobin (HbA1c) measured high significant differences with (11.13 ± 0.55) mmoL/L in patients of diabetes type II. Cholesterol, Triglyceride, LDL-C and VLDL-C high significant differences and highest levels were among patients with Thyroid Dysfunction with Diabetes Mellitus type II: Hypothyroidism with (209.45 ±12.29, 268.18 ±31.57, 114.24 ±13.74 and 55.98 ±5.63) mg/dL respectively, while HDL-C was significantly higher in control group. The Adiponectin had high significant differences among Thyroid Dysfunction: Hyperthyroidism patients with (17.98 ±1.43) ng/mL. In conclusion this data backs up the theory that inducing or suppressing adiponectin in individuals with thyroid dysfunction can help them in losing weight. Hypothyroid individuals with DM Type II and lipid abnormalities in their blood. This data is attributed to the idea that inducing or suppressing adiponectin in individuals with thyroid dysfunction might be a promising new treatment strategy. Adiponectin has been shown that’s involved in numerous physiological and pathological processes, including as inflammation and tissue remodeling. They may be crucial in the formation of adipose tissue and insulin resistance, and they have been linked to a number of inflammatory illnesses.